Kureha Kagaku Kogyo Kabushiki Kaisha

Kureha Chemical Industry Company, Limited

Hideyuki Yamato

Chikao Yoshikumi

Yuji Maeda

Tadaaki Kato

Takayoshi Fujii

Masanori Ikuzawa

Kenichi Saito

Yasuhiko Kobayashi

Fumisato Yoshino

Kyoya Takahata

Naohiro Sonobe

Fumio Hirose

Michihito Ise

Haruhisa Hayashi

Satoshi Mitsuhashi

Noriyuki Toyoda

Susumu Morimoto

Toru Hirai

Sinji Nakajima

Eiji Inoguchi

Masanori Togawa

Mikio Matsuki

An adsorbent for an oral administration, comprising a porous spherical carbonaceous substance wherein a diameter is 0.01 to 1 mm, a specific surface area determined by a BET method is 700 m /g or more, a volume of pores having a pore diameter of 20 to 15000 nm is from not less than 0.04 mL/g to less than 0.10 mL/g, a total amount of acidic groups is 0.30 to 1.20 meq/g, and a total amount of basic groups is 0.20 to 1.00 meq/g, is disclosed.

Adsorbent for oral administration

Disclosed herein is a method for preventing senescence and increasing bone mass namely, bone volume and bone strength which method comprises administering 24,25-dihydroxy cholecalciferol in a pharmaceutically effective amount, and also use of 24,25-dihydroxy cholecalciferol for preparing anti-senescent compositions and compositions for increasing bone mass.

Method for preventing senescence and increasing bone mass

Disclosed herein is a method for inhibiting the formation of urinary calculus by the administration of 24,25-dihydroxycholecarciferol.

Method for inhibiting the formation of urinary calculus utilizing

Disclosed herein is a pharmaceutical composition in dosage unit form, which comprises a dosage effective for treating nephritic disease of a compound of 24,25-dihydroxycholecalciferol as an active ingredient and a pharmaceutically acceptable carrier.

Antinephritic pharmaceutical composition containing 24,

Disclosed herein is a pharmaceutical composition in dosage unit form, which comprises a dosage effective for treating osteoporosis of a compound of 24,25-dihydroxycholecalciferol and a pharmaceutically acceptable carrier.

Antiosteoporotic pharmaceutical composition containing

Disclosed is a pharmaceutical composition in dosage unit form which comprises a dosage effective for the treatment of pains and pyrexia, hypertension, hypotension, hyperlipemia, inflammatory diseases or diseases due to the functional accentuation of thrombocytes of a compound of 24,25-dihydroxycholecalciferol and a pharmaceutical acceptable carrier or diluent therefor.

Pharmaceutical composition containing 24,25-dihydroxycholecalciferol in

Disclosed is a pharmaceutical composition in dosage unit form which comprises a dosage effective for the treatment of myodystrophia of a compound of 24,25-dihydroxycholecalciferol and a pharmaceutical acceptable carrier or diluent therefor.

Pharmaceutical composition containing 24,25-dihydroxycholecalciferol as

Growing community of inventors

Tokyo, Japan

Hideyuki Yamato